COVID-19: Prospective Challenges and Potential Vaccines

Area of Science:

• Virology
• Immunology
• Epidemiology

Background:

• RNA viruses possess remarkable adaptability, enabling them to evolve and transmit from animal reservoirs to human populations.
• The COVID-19 pandemic, caused by SARS-CoV-2, exemplifies zoonotic transmission of an RNA virus, highlighting the urgent need for effective countermeasures.
• Vaccine development and regulatory approval for SARS-CoV-2 present substantial challenges during an active global health crisis.

Purpose of the Study:

• To review the challenges and recent advancements in the development of vaccine candidates targeting COVID-19.
• To explore the complexities associated with RNA virus evolution and host-switching phenomena relevant to emerging infectious diseases.

Main Methods:

• A comprehensive literature review was conducted using databases such as Google Scholar, PubMed, NCBI, and Yahoo.
• Search terms focused on COVID-19 challenges, SARS-CoV-2, RNA virus adaptability, zoonotic transmission, and vaccine development.

Main Results:

• High mutation rates in RNA viruses facilitate survival and host adaptation, as seen in SARS, MERS, and COVID-19 outbreaks.
• As of April 2020, 115 COVID-19 vaccine candidates were under investigation, with 78 active and some in early-stage clinical trials.
• Numerous international pharmaceutical and biotechnology firms are engaged in developing diverse COVID-19 vaccine candidates.

Conclusions:

• Pathogenic RNA viruses pose significant global health risks, with limited understanding of human-host zoonotic transmission mechanisms.
• Elucidating the molecular basis of viral host switching is crucial for preventing future zoonotic transmissions.
• Rapid development and deployment of safe and effective vaccines are paramount for controlling COVID-19 and mitigating future pandemic threats, though timely availability remains a critical hurdle.